BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28455946)

  • 1. Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole.
    Walsh TJ; Moriyama B; Penzak SR; Klein TE; Caudle KE
    Clin Pharmacol Ther; 2017 Aug; 102(2):190. PubMed ID: 28455946
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped.
    Gautier-Veyret E; Fonrose X; Stanke-Labesque F
    Clin Pharmacol Ther; 2017 Aug; 102(2):189. PubMed ID: 28182291
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes.
    Shao B; Ma Y; Li Q; Wang Y; Zhu Z; Zhao H; Sun J; Dong L; Zhu Y; Zhao N; Qin Y
    Xenobiotica; 2017 Dec; 47(12):1121-1129. PubMed ID: 27937048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole".
    Walsh TJ; Moriyama B; Penzak SR; Klein TE; Caudle KE
    Clin Pharmacol Ther; 2018 Feb; 103(2):187. PubMed ID: 28786218
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of CYP3A4 Genotype on Voriconazole Exposure.
    Duflot T; Schrapp A; Bellien J; Lamoureux F
    Clin Pharmacol Ther; 2018 Feb; 103(2):185-186. PubMed ID: 28786228
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations.
    Gautier-Veyret E; Bailly S; Fonrose X; Tonini J; Chevalier S; Thiebaut-Bertrand A; Stanke-Labesque F
    Pharmacogenomics; 2017 Aug; 18(12):1119-1123. PubMed ID: 28745547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections.
    Chuwongwattana S; Jantararoungtong T; Prommas S; Medhasi S; Puangpetch A; Sukasem C
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00665. PubMed ID: 33124772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of
    Zhao T; Shen H; Zhang HL; Feng J; Liu SM; Wang TT; Li HJ; Yu LH
    Pharmacogenomics; 2023 Feb; 24(3):141-151. PubMed ID: 36718992
    [No Abstract]   [Full Text] [Related]  

  • 10. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
    Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
    Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
    Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.
    Gong F; Hu H; Ouyang Y; Liao ZZ; Kong Y; Hu JF; He H; Zhou Y
    Toxicol Appl Pharmacol; 2023 May; 466():116475. PubMed ID: 36931438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of CYP2C19, CYP2C9 and CYP3A4 gene polymorphisms on plasma voriconazole levels in Chinese pediatric patients.
    Fan X; Zhang H; Wen Z; Zheng X; Yang Y; Yang J
    Pharmacogenet Genomics; 2022 Jun; 32(4):152-158. PubMed ID: 35081606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.
    Weiss J; Ten Hoevel MM; Burhenne J; Walter-Sack I; Hoffmann MM; Rengelshausen J; Haefeli WE; Mikus G
    J Clin Pharmacol; 2009 Feb; 49(2):196-204. PubMed ID: 19033450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.
    Huang X; Zhou Y; Zhang J; Xiang H; Mei H; Liu L; Tong L; Zeng F; Huang Y; Zhou H; Zhang Y
    Br J Clin Pharmacol; 2022 Oct; 88(10):4515-4525. PubMed ID: 35508605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites.
    Lee HI; Byeon JY; Kim YH; Lee CM; Choi CI; Jang CG; Bae JW; Lee YJ; Lee SY
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1417-1426. PubMed ID: 30039199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?
    Owusu Obeng A; Egelund EF; Alsultan A; Peloquin CA; Johnson JA
    Pharmacotherapy; 2014 Jul; 34(7):703-18. PubMed ID: 24510446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors.
    Zhu L; Liao S; Wang N; Ge T; Yang J; Xu G; Wang J; Li K; Li G
    Int J Clin Pharmacol Ther; 2016 Aug; 54(8):587-96. PubMed ID: 27191765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole.
    He HR; Sun JY; Ren XD; Wang TT; Zhai YJ; Chen SY; Dong YL; Lu J
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):811-9. PubMed ID: 25515945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes.
    Mirzaev KB; Rytkin E; Ryzhikova KA; Grishina EA; Sozaeva ZA; Fedorinov DS; Konova OD; Giliarov MI; Belyakova GA; Andreev DA; Sychev DA
    Drug Metab Pers Ther; 2018 Sep; 33(3):109-118. PubMed ID: 30171809
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.